Major histocompatibility complex class II molecule in non-small cell lung cancer diagnosis, prognosis and treatment

por Wang, Hao, Zhao, Sha, Zhang, Xiaoshen, Jia, Keyi, Deng, Juan, Zhou, Caicun, He, Yayi
Publicado 2019

OX40 (CD134) and OX40 ligand, important immune checkpoints in cancer

por Deng, Juan, Zhao, Sha, Zhang, Xiaoshen, Jia, Keyi, Wang, Hao, Zhou, Caicun, He, Yayi
Publicado 2019

Prognostic significance of postoperative longitudinal change of serum carcinoembryonic antigen level in patients with stage I lung adenocarcinoma completely resected by single-port...

por Chen, Hao, Jiang, Yan, Jia, Keyi, Zhang, Kaixuan, Matsuura, Natsumi, Jeong, Jin Yong, Su, Bo, Zhou, Xiao
Publicado 2021

Anti PD-1 monoclonal antibody induced autoimmune diabetes mellitus: a case report and brief review

por Li, Wei, Wang, Hao, Chen, Bin, Zhao, Sha, Zhang, Xiaoshen, Jia, Keyi, Deng, Juan, He, Yayi, Zhou, Caicun
Publicado 2020

CD137, an attractive candidate for the immunotherapy of lung cancer

por Ye, Lingyun, Jia, Keyi, Wang, Lei, Li, Wei, Chen, Bin, Liu, Yu, Wang, Hao, Zhao, Sha, He, Yayi, Zhou, Caicun
Publicado 2020

Alterations of DNA damage repair in cancer: from mechanisms to applications

por Jiang, Minlin, Jia, Keyi, Wang, Lei, Li, Wei, Chen, Bin, Liu, Yu, Wang, Hao, Zhao, Sha, He, Yayi, Zhou, Caicun
Publicado 2020

Alterations of DNA damage response pathway: Biomarker and therapeutic strategy for cancer immunotherapy

por Jiang, Minlin, Jia, Keyi, Wang, Lei, Li, Wei, Chen, Bin, Liu, Yu, Wang, Hao, Zhao, Sha, He, Yayi, Zhou, Caicun
Publicado 2021

Advanced lung adenocarcinoma patient with EGFR exon 20 insertion benefits from high-dose furmonertinib for nine months after progression from mobocertinib: a case report

por Jia, Keyi, Yang, Shuo, Chen, Bin, Yu, Jia, Wu, Yan, Li, Wei, Zhou, Fei, Wu, Fengying, Feng, Gaohua, Ren, Shengxiang
Publicado 2022

Early diagnosis of lung cancer: which is the optimal choice?

por Ning, Jing, Ge, Tao, Jiang, Minlin, Jia, Keyi, Wang, Lei, Li, Wei, Chen, Bin, Liu, Yu, Wang, Hao, Zhao, Sha, He, Yayi
Publicado 2021

Expression of PD-1 and PD-L1 on Tumor-Infiltrating Lymphocytes Predicts Prognosis in Patients with Small-Cell Lung Cancer

por Sun, Chenglong, Zhang, Liping, Zhang, Wei, Liu, Yu, Chen, Bin, Zhao, Sha, Li, Wei, Wang, Lei, Ye, Lingyun, Jia, Keyi, Wang, Hao, Wu, Chunyan, He, Yayi, Zhou, Caicun
Publicado 2020

High discrepancy in thrombotic events in non-small cell lung cancer patients with different genomic alterations

por Liu, Yiwei, Wang, Wanying, Wu, Fengying, Gao, Guanghui, Xu, Jian, Li, Xuefei, Zhao, Chao, Yang, Shuo, Mao, Shiqi, Pan, Yingying, Jia, Keyi, Shao, Chuchu, Chen, Bin, Ren, Shengxiang, Zhou, Caicun
Publicado 2021

Patients With Short PFS to EGFR-TKIs Predicted Better Response to Subsequent Anti-PD-1/PD-L1 Based Immunotherapy in EGFR Common Mutation NSCLC

por Liu, Sangtian, Wu, Fengying, Li, Xuefei, Zhao, Chao, Jia, Yijun, Jia, Keyi, Han, Ruoshuang, Qiao, Meng, Li, Wei, Yu, Jia, Zhou, Fei, Xiong, Anwen, Chen, Bin, Fan, Jue, Ren, Shengxiang, Zhou, Caicun
Publicado 2021

Adenocarcinoma of High-Grade Patterns Associated with Distinct Outcome of First-Line Chemotherapy or EGFR-TKIs in Patients of Relapsed Lung Cancer

por Yu, Xiaofei, Dong, Zhengwei, Wang, Wanying, Mao, Shiqi, Pan, Yingying, Liu, Yiwei, Yang, Shuo, Chen, Bin, Wang, Chunyan, Li, Xuefei, Zhao, Chao, Jia, Keyi, Shao, Chuchu, Wu, Chunyan, Ren, Shengxiang, Zhou, Caicun
Publicado 2021

Efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer harboring BRAF mutations

por Wang, Haowei, Cheng, Lei, Zhao, Chao, Zhou, Fei, Jiang, Tao, Guo, Haoyue, Shi, Jinpeng, Chen, Peixin, Tang, Zhuoran, Mao, Shiqi, Jia, Keyi, Ye, Lingyun, Cai, Chenlei, Li, Xuefei, Chen, Xiaoxia, Zhou, Caicun
Publicado 2023

CD39: the potential target in small cell lung cancer

por Chen, Shanhao, Wu, Shengyu, Zhang, Liping, Zhang, Wei, Liu, Yu, Chen, Bin, Zhao, Sha, Li, Wei, Sun, Chenglong, Wang, Lei, Jia, Keyi, Wang, Hao, Chen, Peixin, Wu, Chunyan, Zhu, Junjie, He, Yayi, Zhou, Caicun
Publicado 2020

PD-L1 methylation restricts PD-L1/PD-1 interactions to control cancer immune surveillance

por Huang, Changsheng, Ren, Shengxiang, Chen, Yaqi, Liu, Anyi, Wu, Qi, Jiang, Tao, Lv, Panjing, Song, Da, Hu, Fuqing, Lan, Jingqing, Sun, Li, Zheng, Xue, Luo, Xuelai, Chu, Qian, Jia, Keyi, Li, Yan, Wang, Jun, Zou, Caicun, Hu, Junbo, Wang, Guihua
Publicado 2023

Collection on reports of molecules linked to epithelial-mesenchymal transition in the process of treating metastasizing cancer: a narrative review

por Cai, Yiyi, Wang, Boyuan, Li, Bingying, Huang, Xintong, Guo, Haoyue, Liu, Yu, Chen, Bin, Zhao, Sha, Wu, Shengyu, Li, Wei, Wang, Lei, Jia, Keyi, Wang, Hao, Chen, Peixin, Jiang, Minlin, Tang, Xuzhen, Qi, Hui, Dai, Chunlei, Ye, Junyan, He, Yayi
Publicado 2021

Outcome comparison of pyrotinib with current standard of care in the second/third line setting in advanced non-small cell lung cancer patients with HER2 mutation

por Mao, Shiqi, Luo, Libo, Yang, Shuo, Wang, Yan, Zhou, Fei, Yu, Jia, Chen, Bin, Gao, Guanghui, Li, Xuefei, Zhao, Chao, Cheng, Lei, Liu, Yiwei, Wang, Wanying, Jia, Keyi, Shao, Chuchu, Liu, Xinyu, Chen, Xiaoxia, Su, Chunxia, Zhou, Caicun, Wu, Fengying, Ren, Shengxiang
Publicado 2023

Challenges and countermeasures of thoracic oncology in the epidemic of COVID-19

por Guo, Haoyue, Chen, Xiaoxia, Su, Chunxia, Liu, Yu, Wang, Hao, Sun, Chenglong, Chen, Peixin, Jiang, Minlin, Xu, Yi, Wu, Shengyu, Jia, Keyi, Zhao, Sha, Li, Wei, Chen, Bin, Wang, Lei, Yu, Jia, Xiong, Anwen, Gao, Guanghui, Wu, Fengying, Li, Jiayu, Ye, Lingyun, Bo, Bing, Chen, Shen, Ren, Shengxiang, He, Yayi, Zhou, Caicun
Publicado 2020